Two short approaches to the COVID-19 drug β-<scp>d</scp>-<i>N</i><sup>4</sup>-hydroxycytidine and its prodrug molnupiravir-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two short approaches to the COVID-19 drug β-d-N⁴-hydroxycytidine and its prodrug molnupiravir

Published:2024 Issue:4 Volume:22 Page:735-740
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Persaud Kevin E.¹,Sahu Rajesh R.²,Neary Michelle C.³^ORCID,Kapdi Anant R.²^ORCID,Lakshman Mahesh K.¹^ORCID

Affiliation:

1. Department of Chemistry and Biochemistry, The City College of New York, 160 Convent Avenue, New York, NY 10031, USA

2. Department of Chemistry, Institute of Chemical Technology, Nathalal Parekh Road, Matunga, Mumbai 400019, India

3. Department of Chemistry, Hunter College, 695 Park Avenue, New York, NY 10065, USA

Abstract

Synthesis of the COVID drug β-d-N4-hydroxycytidine (NHC) and its prodrug, molnupiravir, has been achieved via two chemical routes.

Funder

Fulbright U.S. Scholar Program

Air Force Office of Scientific Research

National Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/OB/D3OB02039H

Reference49 articles.

1. COVID-19: Top 60 Drug Treatments in Development

2. The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro

3. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

4. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

5. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Mini-Review on the Common Antiviral Drug Targets of Coronavirus;Microorganisms;2024-03-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3